Factors Contributing to Blood Glucose Elevation Associated With Olanzapine Used As an Antiemetic During Cancer Chemotherapy

Overview

Journal In Vivo

Specialty Oncology

Date 2025 Feb 26

PMID 40010992

Authors

Yuko Kanbayashi

Takeshi Ishikawa

Tetsuya Taguchi

Koichi Takayama

Affiliations

Soon will be listed here.

Abstract

Background/aim: This retrospective study aimed to identify factors contributing to blood glucose elevation associated with olanzapine use and to develop new strategies involving olanzapine aimed at enhancing quality of life in patients undergoing chemotherapy.

Patients And Methods: This study enrolled 220 cancer patients undergoing chemotherapy between January 2017 and May 2022 at our outpatient chemotherapy center. Variables related to the development of olanzapine-associated blood glucose elevation were extracted from medical records for use in regression analysis. We assessed the severity of blood glucose elevation based on the most recent blood glucose level measured after the final administration of olanzapine. Random blood glucose levels were scored as follows: 0, <140 mg/dl; 1, 140-200 mg/dl; or 2, >200 mg/dl. Multivariate ordered logistic regression analysis was performed to identify potential factors in the development of blood glucose elevations associated with olanzapine.

Results: Factors correlated with olanzapine-associated blood glucose elevation included pre-chemotherapy random blood glucose level (=0.002), gastric cancer (=0.003), and the use of calcium channel blockers (=0.048). Although concomitant use of renin-angiotensin system inhibitors showed a tendency toward an association with elevated blood glucose levels, this finding was not statistically significant.

Conclusion: Identifying potential factors contributing to olanzapine-associated blood glucose elevation may assist in developing strategies to improve quality of life for patients undergoing chemotherapy.

References

Kinomura M, Iihara H, Fujii H, Hirose C, Endo J, Yanase K . Effect of Mirtazapine for the Prevention of Nausea and Vomiting in Patients With Thoracic Cancer Receiving Platinum-based Chemotherapy. Anticancer Res. 2023; 43(3):1301-1307. DOI: 10.21873/anticanres.16277. View

Lan N, Zhang L, Zhou Y, Lu Y, Jiao F, Zhao Y . Insulin for hyperglycemia prevention and management during postgastrectomy nutrition support in gastric cancer: Reduced complications in a retrospective cohort study in China. Asia Pac J Clin Nutr. 2022; 31(1):49-56. DOI: 10.6133/apjcn.202203_31(1).0006. View

Seaburg H, McLendon B, Doraiswamy P . Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. Pharmacotherapy. 2001; 21(11):1448-54. DOI: 10.1592/phco.21.17.1448.34421. View

Varma M, Connolly K, Fulton B . Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature. J Intensive Care Med. 2007; 22(1):52-5. DOI: 10.1177/0885066606295823. View

Demissie B, Girmaw F, Amena N, Ashagrie G . Prevalence of metabolic syndrome and associated factors among patient with type 2 diabetes mellitus in Ethiopia, 2023: asystematic review and meta analysis. BMC Public Health. 2024; 24(1):1128. PMC: 11040765. DOI: 10.1186/s12889-024-18580-0. View

Polcwiartek C, Vang T, Bruhn C, Hashemi N, Rosenzweig M, Nielsen J . Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. Psychopharmacology (Berl). 2016; 233(21-22):3663-3672. DOI: 10.1007/s00213-016-4411-x. View

Miyakoshi T, Ishikawa S, Okubo R, Hashimoto N, Sato N, Kusumi I . Risk factors for abnormal glucose metabolism during antipsychotic treatment: A prospective cohort study. J Psychiatr Res. 2023; 168:149-156. DOI: 10.1016/j.jpsychires.2023.10.055. View

Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S . Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support Care Cancer. 2015; 24(2):675-682. DOI: 10.1007/s00520-015-2829-z. View

De Hert M, Dobbelaere M, Sheridan E, Cohen D, Correll C . Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011; 26(3):144-58. DOI: 10.1016/j.eurpsy.2010.09.011. View

10.

Fukao K, Shimada K, Hiki M, Kiyanagi T, Hirose K, Kume A . Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and.... Cardiovasc Diabetol. 2011; 10:79. PMC: 3179711. DOI: 10.1186/1475-2840-10-79. View

11.

Kutney K, Kaminski B, Casey T, ORiordan M, Gubitosi-Klug R . Reproducibility of in-home CFRD screening using continuous glucose monitoring and mixed meal tolerance test. J Clin Transl Endocrinol. 2023; 33:100323. PMC: 10495624. DOI: 10.1016/j.jcte.2023.100323. View

12.

Yao J, Fan S, Shi X, Gong X, Zhao J, Fan G . Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers on insulin sensitivity in hypertensive patients: A meta-analysis of randomized controlled trials. PLoS One. 2021; 16(7):e0253492. PMC: 8263258. DOI: 10.1371/journal.pone.0253492. View

13.

Koller E, Doraiswamy P . Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002; 22(7):841-52. DOI: 10.1592/phco.22.11.841.33629. View

14.

Tamura T, Kawakado K, Makimoto G, Nakanishi M, Kuyama S . Effect of Prophylactic Anti-emetics on Opioid-induced Nausea and Vomiting: A Retrospective Observational Cohort Study. In Vivo. 2021; 35(3):1737-1742. PMC: 8193312. DOI: 10.21873/invivo.12432. View

15.

Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T . Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 21(2):242-249. DOI: 10.1016/S1470-2045(19)30678-3. View

16.

Nawa-Nishigaki M, Kobayashi R, Suzuki A, Hirose C, Matsuoka R, Mori R . Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer. Anticancer Res. 2018; 38(2):877-884. DOI: 10.21873/anticanres.12297. View

17.

Nakashima K, Murakami H, Yokoyama K, Omori S, Wakuda K, Ono A . A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. Jpn J Clin Oncol. 2017; 47(9):840-843. DOI: 10.1093/jjco/hyx084. View

18.

Zhan Z, Chen Y, Huang Z, Luo Y, Zeng J, Wang Y . Metabolic syndrome, its components, and gastrointestinal cancer risk: a meta-analysis of 31 prospective cohorts and Mendelian randomization study. J Gastroenterol Hepatol. 2024; 39(4):630-641. DOI: 10.1111/jgh.16477. View

19.

Bloch Y, Vardi O, Mendlovic S, Levkovitz Y, Gothelf D, Ratzoni G . Hyperglycemia from olanzapine treatment in adolescents. J Child Adolesc Psychopharmacol. 2003; 13(1):97-102. DOI: 10.1089/104454603321666234. View

20.

Zajecka J, Weisler R, Sachs G, Swann A, Wozniak P, Sommerville K . A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2003; 63(12):1148-55. DOI: 10.4088/jcp.v63n1210. View